Acme United (ACU) Q1 2026: MyMedic Adds 8% to Sales, Margin Hit from Tariffs Lingers

April 23, 2026 | By EarningsIQ Research

Acme United’s first quarter saw strong top-line growth from the MyMedic acquisition, but profitability was pressured by tariff-driven cost inflation and integration spending. Management expects gross margin normalization by Q3 as high-tariff inventory cycles out, and is prioritizing automation to offset structural cost headwinds. Investors should watch for the pace of MyMedic retail expansion and the impact of ongoing supply chain and geopolitical risks on cost structure and inventory levels.

Summary

• Margin Compression from Tariffs: Elevated input costs and tariffs weighed on core gross margins despite higher sales.
• Integration and Automation Focus: MyMedic and Schmiedeglut integration aims to expand DTC capabilities and operational efficiency.
• Inventory Buffering for Geopolitical Risk: $10 million in extra inventory stockpiled to hedge against supply shocks from Middle East conflict.

Performance Analysis

Acme United delivered a 14% sales increase in Q1 2026, with the bulk of the incremental growth attributable to the recently acquired MyMedic, direct-to-consumer (DTC) first aid business, which contributed about 8% of total sales. Excluding MyMedic, organic growth was 6%, driven by solid performance in first aid and medical products across the U.S., Europe, and Canada. The European and Canadian segments both posted double-digit growth in local currency, with Europe up 19% and Canada up 11%.

Profitability metrics, however, deteriorated meaningfully. Net income fell sharply as gross margin expansion from high-margin MyMedic sales was offset by elevated tariffs and one-time MedNap quality assurance costs. Core gross margin, excluding MyMedic, declined by approximately 200 basis points, reflecting the full impact of high-tariff inventory flowing through cost of goods sold. SG&A as a percentage of sales increased due to heavier advertising and integration expenses, especially for the DTC channel.

• Tariff Drag on Legacy Margins: Core gross margin contracted by about 2 percentage points, directly tied to tariff pass-through.
• SG&A Inflation: Operating expenses rose to 36% of sales, up from 34% last year, reflecting both integration and DTC marketing costs.
• Net Debt Expansion: Balance sheet leverage increased, reflecting the MyMedic acquisition, facility investments, and inventory buildup.

Despite these headwinds, management expects margin relief starting in Q3 as lower-tariff inventory replaces higher-cost stock and as one-off MedNap expenses subside. Automation projects and facility consolidation are expected to drive future productivity gains.

Executive Commentary

Strategic Positioning

1. Direct-to-Consumer Expansion

MyMedic and Schmiedeglut, both DTC acquisitions, are being leveraged to build out Acme’s digital sales and marketing expertise. MyMedic’s half-million-strong social media following provides a ready platform for new product introductions and cross-selling, with plans to extend DTC learnings to other brands, especially in crafts and first aid.

2. Automation and Productivity Investments

Robotics and process automation are central to Acme’s cost mitigation strategy. Projects span packaging automation at the new Spill Magic facility, robotics for lens wipes at Brooksville, and drones for inventory management at Rocky Mount. These investments, totaling several million dollars annually, are aimed at reducing labor costs and supporting scalable growth.

3. Inventory and Supply Chain Resilience

Acme has proactively built a $10 million inventory buffer in response to the war in Iran and broader supply chain volatility. This hedges against potential shortages and price spikes but ties up capital and increases carrying costs, pressuring near-term cash flow and leverage metrics.

4. Facility and Capacity Expansion

The new $6 million Spill Magic facility in Tennessee is now operational, consolidating production and enabling future growth. Canadian operations are adding 30% more capacity to meet rising demand, with MyMedic product launches planned for this year.

5. Tariff and Regulatory Adaptation

Management is navigating a volatile tariff landscape, with core margins expected to recover as lower-tariff inventory cycles in. MedNap quality upgrades, driven by FDA requirements, are mostly complete, positioning the business for improved compliance and hospital market access.

Key Considerations

This quarter’s results reflect a company in active transition, balancing growth from new channels and acquisitions with acute cost and integration pressures. The next two quarters will be critical in demonstrating margin normalization and realizing synergy capture.

Key Considerations:

• DTC Channel Scaling: MyMedic’s DTC model offers higher gross margins but requires sustained marketing investment and operational discipline to drive profitability.
• Tariff and Cost Pressure Relief: Margin recovery hinges on the pace at which high-tariff inventory is replaced and on the absence of further trade shocks.
• Integration Execution: Realizing cost synergies and cross-selling from MyMedic and Schmiedeglut will determine the long-term accretive value of these deals.
• Automation ROI: Payback on robotics and process automation must materialize to offset rising labor and SG&A costs.
• Balance Sheet Flexibility: Elevated net debt from acquisitions and inventory buildup reduces near-term financial flexibility.

Risks

Acme United faces continued risk from tariff volatility, as further geopolitical escalation or trade policy shifts could prolong cost pressure. The $10 million inventory buildup hedges against shortages but increases working capital and debt risk. Integration of DTC acquisitions carries execution risk, while automation investments must deliver productivity gains to justify capital outlays. Regulatory scrutiny, particularly at MedNap, remains a watchpoint for both expenses and market access.

Forward Outlook

For Q2 2026, Acme United expects:

• Tariff impact to begin moderating as lower-cost inventory flows through
• SG&A to remain elevated but one-time MedNap expenses to subside

For full-year 2026, management maintained its focus on:

• Margin normalization by Q3 as tariff effects wane
• Continued DTC expansion and automation-driven productivity gains

Management highlighted several factors that could affect results:

• Potential for further inventory cost inflation if Middle East conflict escalates
• Timing and scale of MyMedic retail distribution gains

Takeaways

Acme United’s Q1 2026 underscores the tension between top-line growth and near-term margin pressure as the company integrates DTC acquisitions and absorbs external cost shocks.

• Tariff Drag Remains Material: Margin recovery is highly dependent on trade policy stability and inventory cycling, with relief not expected until Q3.
• DTC and Automation Are Strategic Levers: Success in scaling MyMedic and extracting automation ROI will shape future earnings power.
• Monitor Inventory and Integration Execution: Investors should track inventory normalization and signs of synergy realization from recent acquisitions.

Conclusion

Acme United’s Q1 was defined by strong sales momentum from acquisitions but meaningful margin and earnings pressure from tariffs and integration spending. The next phase will test management’s ability to deliver on margin recovery, DTC channel scaling, and automation payback, all while navigating ongoing macro and geopolitical uncertainty.

Industry Read-Through

Acme’s experience this quarter highlights the acute impact of tariffs and supply chain disruptions on mid-sized consumer and medical product manufacturers. The shift toward direct-to-consumer models, paired with aggressive automation, is becoming a necessity for margin defense as traditional retail channels face volatility. Inventory buffering as a hedge against geopolitical risk is likely to be a recurring theme across the sector, though it raises balance sheet risk. Competitors and peers should expect continued cost and margin volatility, with technology and channel diversification as key differentiators in the current environment.

ACU Industrials Consumer Products Automation Direct-to-Consumer Tariffs Inventory